Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA.
Gaillard SL, et al.
Gynecol Oncol. 2019 Jul;154(1):199-206. doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13.
Gynecol Oncol. 2019.
PMID: 30987772